financetom
Business
financetom
/
Business
/
Harley-Davidson forecasts 2025 motorcycle revenue flat to down 5%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Harley-Davidson forecasts 2025 motorcycle revenue flat to down 5%
Feb 5, 2025 4:18 AM

Feb 5 (Reuters) - Harley-Davidson ( HOG ) said on

Wednesday it expects 2025 motorcycle revenue to be flat to down

5%, as consumers pulled back from big-ticket purchases.

The company also reported a net loss of $117 million, or 93

cents per share, for the fourth quarter, compared with a profit

of $26 million, or 18 cents per share, a year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chevron seeks diversified approach to refinery investment
Chevron seeks diversified approach to refinery investment
Sep 8, 2025
SINGAPORE, Sept 8 (Reuters) - Chevron ( CVX ) is looking to have a balanced portfolio of refineries, Brant Fish, the U.S. major's president, international products, said at the APPEC event in Singapore. There'll be places like Korea where we go investment heavy in petrochemicals and in heavy oil upgrading, Fish said of the firm's existing investments. And then there'll...
Cerence, Microsoft Team Up to Bring Voice-First Work Assistant to Cars
Cerence, Microsoft Team Up to Bring Voice-First Work Assistant to Cars
Sep 8, 2025
03:45 AM EDT, 09/08/2025 (MT Newswires) -- Cerence ( CRNC ) said Monday it has partnered with Microsoft ( MSFT ) to bring to market a new artificial intelligence-based mobile work assistant. The company said the offering will run on its xUI platform and will integrate Microsoft ( MSFT ) 365 Copilot tools like Outlook, Teams and OneNote, allowing users...
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Sep 8, 2025
04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed clinically meaningful and statistically significant improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period. The 92-patient study met its primary endpoint of improvements in mean...
Johnson & Johnson Says Potential Non-Small Cell Lung Cancer Treatment Improves Overall Survival
Johnson & Johnson Says Potential Non-Small Cell Lung Cancer Treatment Improves Overall Survival
Sep 8, 2025
03:49 AM EDT, 09/08/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday results of a phase 3 study of Rybrevant plus Lazcluze as a potential treatment for certain patients with locally advanced or metastatic non-small cell lung cancer showed statistically significant and clinically meaningful overall survival improvement. At a median follow-up of 37.8 months, the drug combination...
Copyright 2023-2026 - www.financetom.com All Rights Reserved